Guided Therapeutics (GTHP) Cash & Equivalents Growth (3y) (2013 - 2026)
Guided Therapeutics (GTHP) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -13.31% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 34.27% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 8.10% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 8.16% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 40.74% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -2.57% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 2.72% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 38.28% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 32.23% |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | -79.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.33% |
| Dec 31, 2025 | -69.91% |
| Sep 30, 2025 | -68.17% |
| Jun 30, 2025 | -25.42% |
| Mar 31, 2025 | -45.87% |
| Dec 31, 2024 | -15.50% |
| Sep 30, 2024 | -28.95% |
| Jun 30, 2024 | -33.19% |
| Mar 31, 2024 | -29.07% |
| Dec 31, 2023 | 48.08% |
| Sep 30, 2023 | 7.96% |
| Jun 30, 2023 | 21.19% |
| Mar 31, 2023 | 343.91% |
| Dec 31, 2022 | 37.03% |
| Mar 31, 2022 | 394.38% |
| Sep 30, 2021 | 97.71% |
| Jun 30, 2021 | 182.26% |
| Mar 31, 2021 | 154.11% |
| Dec 31, 2020 | 466.71% |
| Sep 30, 2020 | 98.75% |